Samsung Biosimilar, 25% Increase in European Sales in Q1

Biosimilars for autoimmune diseases developed by Samsung Bioepis: Benepali (from the left), Imraldi, and Flixabi.

[Asia Economy Reporter Choi Dae-yeol] Sales of Samsung Bioepis' autoimmune disease treatments in Europe during the first quarter increased by more than 25% compared to the same period last year.

According to Biogen's first-quarter earnings announced on the 22nd (local time), the total sales of Samsung Bioepis' three biosimilars?Benepali, Imraldi, and Flixabi?amounted to $218.8 million. Biogen is Samsung Bioepis' marketing partner in the European region. Considering that $174.4 million worth was sold in the first quarter of last year, this represents a 25% increase, marking the first time these three treatments have exceeded $200 million in quarterly sales.

By product, Benepali (SB4, Enbrel biosimilar) recorded $133.5 million, an 8% increase from the first quarter of last year. This drug is reported to have a higher market share than the original drug Enbrel in major European countries such as Germany. Imraldi (SB5, Humira biosimilar) sales rose 73% to $61.6 million during the same period, and Flixabi (SB2, Remicade biosimilar) increased by 61% to $23.7 million.

The company stated, "Imraldi's product sales more than doubled, achieving a market share of over 10% among all European adalimumab-containing drugs, including the original drug Humira. We increased product sales by proactively addressing various risks in preparation for the spread of COVID-19 in Europe."

This content was produced with the assistance of AI translation services.